1
|
Delmé C, Jackson N, Class B, Strickland K, Potvin DA, Frère CH. Adaptive significance of affiliative behaviour differs between sexes in a wild reptile population. Proc Biol Sci 2023; 290:20230805. [PMID: 37339740 PMCID: PMC10281801 DOI: 10.1098/rspb.2023.0805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 05/22/2023] [Indexed: 06/22/2023] Open
Abstract
In recent years, we have begun to appreciate that social behaviours might exhibit repeatable among-individual variation. Such behavioural traits may even covary and have critical evolutionary implications. Importantly, some social behaviours such as aggressiveness have been shown to provide fitness benefits, including higher reproductive success and survival. However, fitness consequences of affiliative behaviours, especially between or among sexes, can be more challenging to establish. Using a longitudinal behavioural dataset (2014-2021) collected on eastern water dragons (Intellagama lesueurii), we investigated whether various aspects of affiliative behaviour (i) were repeatable across years, (ii) covaried with each other at the among-individual level, and (iii) influenced individuals' fitness. In particular, we considered affiliative behaviours towards opposite-sex and same-sex conspecifics separately. We found that social traits were repeatable and covaried with each other similarly for both sexes. More notably, we found that male reproductive success was positively correlated with the number of female associates and the proportion of time spent with females, while females' reproductive success was not correlated with any of the measured social behaviour metrics. Overall, these findings suggest that selection may be acting differently on social behaviour of male and female eastern water dragons.
Collapse
Affiliation(s)
- C. Delmé
- School of Science, Technology and Engineering, University of the Sunshine Coast, Queensland, Australia
| | - N. Jackson
- School of Biological Sciences, University of Queensland, Brisbane, Queensland, Australia
| | - B. Class
- School of Science, Technology and Engineering, University of the Sunshine Coast, Queensland, Australia
- Ludwig-Maximilians-Universität München, Munich, Germany
| | - K. Strickland
- Institute of Ecology and Evolution, School of Biological Sciences, University of Edinburgh, Edinburgh, UK
| | - D. A. Potvin
- School of Science, Technology and Engineering, University of the Sunshine Coast, Queensland, Australia
| | - C. H. Frère
- School of Biological Sciences, University of Queensland, Brisbane, Queensland, Australia
| |
Collapse
|
2
|
Paterson C, Roberts C, Li J, Chapman M, Strickland K, Johnston N, Law E, Bacon R, Turner M, Mohanty I, Pranavan G, Toohey K. What are the experiences of supportive care in people affected by brain cancer and their informal caregivers: A qualitative systematic review. J Cancer Surviv 2023:10.1007/s11764-023-01401-5. [PMID: 37256499 DOI: 10.1007/s11764-023-01401-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Accepted: 05/05/2023] [Indexed: 06/01/2023]
Abstract
PURPOSE To critically synthesise qualitative research to understand experiences of supportive care in people affected by brain cancer and their informal caregivers. METHODS A qualitative systematic review was conducted according to the Joanna Briggs methodology and has been reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Guidelines. Electronic databases were searched by an expert systematic review librarian for all qualitative studies irrespective of research design. All publications were double screened by two reviewers using a pre-determined exclusion and inclusion criteria. The review was managed using Covidence systematic review software. Methodological quality assessment and data extraction were performed. Qualitative findings accompanied by illustrative quotes from included studies were extracted and grouped into categories, which created the overall synthesised findings. RESULTS A total of 33 studies were included which represented a total sample of 671 participants inclusive of 303 patients and 368 informal caregivers. There was a total of 220 individual findings included in this review, which were synthesised into two findings (1) caregivers and patients perceived supports which would have been helpful and (2) caregiver and patient experiences of unmet supportive care needs. CONCLUSION This review highlighted the suffering and distress caused by brain cancer and associated treatments. Both patients and their informal caregivers experienced disconnect from themselves in renegotiating roles, and a profound sense of loneliness as the physical deterioration of the disease progressed. Both patients and informal caregivers reported similar unmet needs within the current service provision for brain cancer. However, what is apparent is that current cancer services are provided solely for patients, with little or no consideration to the support needs of both the patient and their informal caregiver. Service re-design is needed to improve care coordination with individualised informational support, implementation of holistic needs assessments for both the patients and their caregivers, better community support provision, improved opportunities for emotional care with early referral for palliative care services. IMPLICATIONS FOR CANCER SURVIVORS It is recommended that members of the multidisciplinary brain cancer team reflect on these findings to target holistic needs assessments and develop shared self-management care plans for both the patient and the informal caregiver.
Collapse
Affiliation(s)
- C Paterson
- Faculty of Health, University of Canberra, Bruce, Canberra, ACT, Australia.
- Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research Group, University of Canberra, Bruce, Canberra, ACT, Australia.
- School of Nursing, Midwifery and Public Health, University of Canberra, Bruce, Canberra, ACT, Australia.
- Canberra Health Services and ACT Health, Garran, Canberra, Australia.
- Robert Gordon University, Aberdeen, Scotland, UK.
| | - C Roberts
- Faculty of Health, University of Canberra, Bruce, Canberra, ACT, Australia
- Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research Group, University of Canberra, Bruce, Canberra, ACT, Australia
- School of Nursing, Midwifery and Public Health, University of Canberra, Bruce, Canberra, ACT, Australia
| | - J Li
- Canberra Health Services and ACT Health, Garran, Canberra, Australia
| | - M Chapman
- Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research Group, University of Canberra, Bruce, Canberra, ACT, Australia
- Department of Palliative Care, Canberra Health Services, Garran, Canberra, Australia
- School of Medicine and Psychology, Australian National University, Canberra, Australia
| | - K Strickland
- School of Nursing, Midwifery and Public Health, University of Canberra, Bruce, Canberra, ACT, Australia
- School of Nursing & Midwifery, Edith Cowan University, Joondalup, WA, Australia
- School of Clinical Sciences, Faculty of Health and Environmental Sciences, AUT, Auckland, New Zealand
| | - N Johnston
- Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research Group, University of Canberra, Bruce, Canberra, ACT, Australia
- School of Nursing, Midwifery and Public Health, University of Canberra, Bruce, Canberra, ACT, Australia
- Canberra Health Services and ACT Health, Garran, Canberra, Australia
| | - E Law
- Icon Cancer Centre, Canberra, Australia
| | - R Bacon
- Faculty of Health, University of Canberra, Bruce, Canberra, ACT, Australia
- Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research Group, University of Canberra, Bruce, Canberra, ACT, Australia
| | - M Turner
- Faculty of Health, University of Canberra, Bruce, Canberra, ACT, Australia
- Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research Group, University of Canberra, Bruce, Canberra, ACT, Australia
| | - I Mohanty
- Faculty of Health, University of Canberra, Bruce, Canberra, ACT, Australia
| | - G Pranavan
- Canberra Health Services and ACT Health, Garran, Canberra, Australia
| | - K Toohey
- Faculty of Health, University of Canberra, Bruce, Canberra, ACT, Australia
- Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research Group, University of Canberra, Bruce, Canberra, ACT, Australia
| |
Collapse
|
3
|
Frère CH, O'Reilly GD, Strickland K, Schultz A, Hohwieler K, Hanger J, de Villiers D, Cristescu R, Powell D, Sherwin W. Evaluating the genetic consequences of population subdivision as it unfolds and how to best mitigate them: A rare story about koalas. Mol Ecol 2023; 32:2174-2185. [PMID: 36756702 DOI: 10.1111/mec.16877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2022] [Revised: 01/23/2023] [Accepted: 01/25/2023] [Indexed: 02/10/2023]
Abstract
The genetic consequences of the subdivision of populations are regarded as significant to long-term evolution, and research has shown that the scale and speed at which this is now occurring is critically reducing the adaptive potential of most species which inhabit human-impacted landscapes. Here, we provide a rare and, to our knowledge, the first analysis of this process while it is happening and demonstrate a method of evaluating the effect of mitigation measures such as fauna crossings. We did this by using an extensive genetic data set collected from a koala population which was intensely monitored during the construction of linear transport infrastructure which resulted in the subdivision of their population. First, we found that both allelic richness and effective population size decreased through the process of population subdivision. Second, we predicted the extent to which genetic drift could impact genetic diversity over time and showed that after only 10 generations the resulting two subdivided populations could experience between 12% and 69% loss in genetic diversity. Lastly, using forward simulations we estimated that a minimum of eight koalas would need to disperse from each side of the subdivision per generation to maintain genetic connectivity close to zero but that 16 koalas would ensure that both genetic connectivity and diversity remained unchanged. These results have important consequences for the genetic management of species in human-impacted landscapes by showing which genetic metrics are best to identify immediate loss in genetic diversity and how to evaluate the effectiveness of any mitigation measures.
Collapse
Affiliation(s)
- C H Frère
- School of Biological Sciences, University of Queensland, St Lucia, Queensland, Australia
| | - G D O'Reilly
- The School of Biological, Earth and Environmental Sciences, University of New South Wales, Sydney, New South Wales, Australia
| | - K Strickland
- Institute of Ecology and Evolution, University of Edinburgh, Edinburgh, UK
| | - A Schultz
- Icelandic Museum of Natural History (Náttúruminjasafn Íslands), Reykjavik, Iceland
| | - K Hohwieler
- School of Science, Technology and Engineering, University of the Sunshine Coast, Queensland, Australia
| | - J Hanger
- Endeavour Veterinary Ecology Pty Ltd, Toorbul, Queensland, Australia
| | - D de Villiers
- Endeavour Veterinary Ecology Pty Ltd, Toorbul, Queensland, Australia
| | - R Cristescu
- School of Science, Technology and Engineering, University of the Sunshine Coast, Queensland, Australia
| | - D Powell
- School of Science, Technology and Engineering, University of the Sunshine Coast, Queensland, Australia
| | - W Sherwin
- The School of Biological, Earth and Environmental Sciences, University of New South Wales, Sydney, New South Wales, Australia
| |
Collapse
|
4
|
Strickland K, Levengood A, Foroughirad V, Mann J, Krzyszczyk E, Frère CH. Correction to: A framework for the identification of long-term social avoidance in longitudinal datasets. R Soc Open Sci 2022; 9:220017. [PMID: 35116171 PMCID: PMC8767182 DOI: 10.1098/rsos.220017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
[This corrects the article DOI: 10.1098/rsos.170641.][This corrects the article DOI: 10.1098/rsos.170641.].
Collapse
|
5
|
Paterson C, Kozlovskaia M, Turner M, Strickland K, Roberts C, Ogilvie R, Pranavan G, Craft P. Identifying the supportive care needs of men and women affected by chemotherapy-induced alopecia? A systematic review. J Cancer Surviv 2020; 15:14-28. [PMID: 32683651 DOI: 10.1007/s11764-020-00907-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Accepted: 06/14/2020] [Indexed: 02/07/2023]
Abstract
PURPOSE To systematically evaluate evidence regarding the unmet supportive care needs of men and women affected by chemotherapy-induced alopecia (CIA) to inform clinical practice guidelines. METHODS We performed a review of CINAHL, MEDLINE, PsychINFO, Scopus, the Cochrane Library (CCRT and CDSR) controlled trial databases and clinicaltrials.gov from January 1990 to June 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Twenty-seven publications were selected for inclusion in this analysis. RESULTS Included reports used qualitative (ten) and quantitative (17) studies. Across these studies men and women reported the major impact that CIA had on their psychological well-being, quality of life and body image. Hair loss had a negative impact irrespective of gender, which resulted in feelings of vulnerability and visibility of being a "cancer patient". Men and women described negative feelings, often similar, related to CIA with a range of unmet supportive care needs. CONCLUSIONS Some patients are not well-prepared for alopecia due to a lack of information and resources to reduce the psychological burden associated with CIA. Hair loss will affect each patient and their family differently, therefore, intervention and support must be tailored at an individual level of need to optimise psychological and physical well-being and recovery. IMPLICATIONS FOR CANCER SURVIVORS People affected by CIA may experience a range of unmet supportive care needs, and oncology doctors and nurses are urged to use these findings in their everyday consultations to ensure effective, person-centred care and timely intervention to minimise the sequalae associated with CIA.
Collapse
Affiliation(s)
- C Paterson
- Faculty of Health, School of Nursing, Midwifery & Public Health, University of Canberra ACT, Canberra, 2601, Australia.
- Australian Capital Territory (ACT) Health & Canberra Health Services, Canberra, Australia.
- SYNERGY Nursing & Midwifery, Research Centre, ACT Health Directorate, Canberra Hospital, Canberra, Australia.
- Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research group, University of Canberra, Canberra, ACT, Australia.
- Robert Gordon University, Aberdeen, Scotland.
| | - M Kozlovskaia
- Faculty of Health, School of Nursing, Midwifery & Public Health, University of Canberra ACT, Canberra, 2601, Australia
- SYNERGY Nursing & Midwifery, Research Centre, ACT Health Directorate, Canberra Hospital, Canberra, Australia
| | - M Turner
- Faculty of Health, School of Nursing, Midwifery & Public Health, University of Canberra ACT, Canberra, 2601, Australia
| | - K Strickland
- Faculty of Health, School of Nursing, Midwifery & Public Health, University of Canberra ACT, Canberra, 2601, Australia
- SYNERGY Nursing & Midwifery, Research Centre, ACT Health Directorate, Canberra Hospital, Canberra, Australia
- Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research group, University of Canberra, Canberra, ACT, Australia
| | - C Roberts
- Faculty of Health, School of Nursing, Midwifery & Public Health, University of Canberra ACT, Canberra, 2601, Australia
- Prehabilitation, Activity, Cancer, Exercise and Survivorship (PACES) Research group, University of Canberra, Canberra, ACT, Australia
| | - R Ogilvie
- Faculty of Health, School of Nursing, Midwifery & Public Health, University of Canberra ACT, Canberra, 2601, Australia
- Australian Capital Territory (ACT) Health & Canberra Health Services, Canberra, Australia
- SYNERGY Nursing & Midwifery, Research Centre, ACT Health Directorate, Canberra Hospital, Canberra, Australia
| | - G Pranavan
- Australian Capital Territory (ACT) Health & Canberra Health Services, Canberra, Australia
- Australian National University, Canberra, Australia
| | - P Craft
- Australian Capital Territory (ACT) Health & Canberra Health Services, Canberra, Australia
- Australian National University, Canberra, Australia
| |
Collapse
|
6
|
Gerratana L, Zhang Q, Wang C, Shah A, Davis AA, Ye Z, Zhang Y, Abu-Khalaf M, Flaum L, Strickland K, Rossi G, Behdad A, Gradishar W, Platanias L, Yang H, Cristofanilli M. Abstract P5-17-03: How is inflammatory breast cancer (IBC) different? Integration of clinico-pathological features and circulating tumor cells (CTCs)-based biomarkers for disease and prognostic assessment. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-17-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Since IBC is rare and burdened by a particularly unfavorable prognosis, biomarkers able to enhance diagnosis and risk assessment are of pivotal importance and a current unmet need. The aim of this study is to integrate standard clinico-pathological features with CTCs-based biomarkers for a more objective and detailed characterization of IBC.
Methods: This study analyzed retrospectively 251 Advanced Breast Cancer (BC) patients (pts) longitudinally characterized for CTCs and CTCs-based biomarkers at Thomas Jefferson University (Philadephia, PA) and Northwestern University (Chicago. IL). CTCs were enumerated through the CellSearch system (Menarini Silicon Biosystems), and characterized for HER2 expression using the CellSearch CXC Kit. Pts were defined as stage IV aggressive based on the previously reported ≥5 CTCs cut-off (Davis et al. 2018). Associations between clinical features, CTC-derived biomarkers and IBC were tested through uni and multivariate logistic regression. Survival was tested though log-rank test.
Results: Within the analyzed cases, 46% were diagnosed with IBC and among them, 38% was stage IV aggressive. CTC clusters (CTC_CL) were detectable in 12.5% of pts and HER2 positive CTCs (HER2_CTC) in 29.5%. Notably, IBC patients (pts) had a significantly lower CTC count with respect to non-IBC (median 2.5 vs 0 respectively for non-IBC and IBC; P=0.019). BC subtype (HER2 positive BC: OR 2.97; Triple negative BC: OR 2.13), liver and bone involvement (liver: OR 0.46; bone involvement: OR 0.31) were the only significant clinico-pathological features associated with IBC at univariate logistic regression. Interestingly, a marginal significance was observed for soft tissue involvement (OR 1.65, 95%CI 0.95 - 2.87, P=0.07). Stage IV aggressive and presence of HER2_CTC at baseline were moreover inversely associated with IBC. The multivariate model confirmed the significant association between IBC and HER2 positive BC subtype (OR 2.64, 95%CI 1.08 - 6.48, P=0.034), absence of bone involvement (OR 0.31, 95%CI 0.14 - 0.68, P=0.003) and absence of HER2_CTC (OR 0.38, 95%CI 0.15 - 0.98, P=0.045). The baseline detection of CTC_CL was a strong predictor of prognosis for OS in IBC pts (median OS (mOS) 7.6 months (mts) vs not reached (NR) respectively for detectable vs non-detectable CTC_CL; P<0.0001), while a trend was observed for HER2_CTC (mOS 9.9 mts vs NR respectively for detectable vs non-detectable HER2_CTC; P<0.082). Pts negative for CTC_CL at baseline had higher odds of developing CTC_CL in later time-points if stage IV aggressive (OR 12.27, 95%CI 2.10 - 71.57, P=0.005). Despite no baseline factors were significantly associated with the onset of HER2_CTC in later time-points, a trend (P=0.05) was observed for patients without lymph node involvement (OR: 5) and with bone involvement (OR: 4.3).
Conclusion: HER2_CTC and in particular CTC_CL are promising prognostic predictors in IBC. Stage IV aggressive IBC pts could benefit from a longitudinal CTCs assessment, being more prone to develop CTC_CL and therefore at higher risk of rapid disease progression. Probably due to the tropism for soft tissue, IBC is characterized by a lower number of HER2_CTC.
Citation Format: Gerratana L, Zhang Q, Wang C, Shah A, Davis AA, Ye Z, Zhang Y, Abu-Khalaf M, Flaum L, Strickland K, Rossi G, Behdad A, Gradishar W, Platanias L, Yang H, Cristofanilli M. How is inflammatory breast cancer (IBC) different? Integration of clinico-pathological features and circulating tumor cells (CTCs)-based biomarkers for disease and prognostic assessment [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-17-03.
Collapse
Affiliation(s)
- L Gerratana
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - Q Zhang
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - C Wang
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - A Shah
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - AA Davis
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - Z Ye
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - Y Zhang
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - M Abu-Khalaf
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - L Flaum
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - K Strickland
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - G Rossi
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - A Behdad
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - W Gradishar
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - L Platanias
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - H Yang
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| | - M Cristofanilli
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, Italy
| |
Collapse
|
7
|
Shah AN, Gerratana L, Davis AA, Zhang Q, Zhang Y, Rossi G, Wang C, Strickland K, Yang H, Flaum L, Abu-Khalaf M, Behdad A, Ye Z, Platanias L, Gradishar WJ, Cristofanilli M. Abstract P3-01-19: HER2-positive circulating tumor cells (CTCs) in advanced breast cancer (BC): A feature independent of BC subtype. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-01-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: HER2 overexpression is observed on CTCs in advanced BC (ABC), but their significance is not known. We aimed to describe clinical, pathologic, and molecular associations with HER2 overexpression on CTCs in ABC patients (pts).
Methods: We conducted a retrospective analysis of data from ABC pts treated at Thomas Jefferson University and Northwestern University who had evaluation of CTCs and circulating tumor DNA (ctDNA). CTCs were enumerated with the CellSearch immunomagnetic kit (Menarini Silicon Biosystems), HER2 expression on CTCs was evaluated using the CellSearch CXC Kit, and ctDNA was analyzed using the Guardant360 NGS assay (Guardant Health). Associations with the presence of HER2+ CTCs were explored through univariate and multivariate logistic regression. Kruskal-Wallis testing evaluating HER2+ CTCs as a continuous variable was also conducted to confirm consistency of findings. Time to development of HER2+ CTCs was evaluated using Cox proportional hazards regression analysis.
Results: Baseline CTCs were evaluated in 209 pts (10% stage III, 90% stage IV) of whom 41% had no detectable CTCs, 23% had 1-4 CTCs, and 36% had >5 CTCs (stage IV aggressive). Twelve percent had CTC clusters. At least 1 HER2+ CTC was seen in 33% of pts at baseline draw. Of 39 patients with HER2+ BC, only 18% had HER2+ CTCs. Of patients with HER2+ CTCs, 55% had hormone receptor positive BC, 28% had triple negative BC, and 18% had HER2+ BC. On univariate logistic analysis, BC subtype or HER2 status was not associated with the presence of HER2+ CTCs. IBC pts represented 52% of pts and were less likely to have HER2+ CTCs (OR 0.40 95% CI 0.19-0.84). Bone metastases were associated with an increased likelihood of HER2+ CTCs (OR 2.46, 95% CI 1.12-5.38); however, other sites of metastases and number of metastatic sites were not correlated with HER2+ CTCs. Aggressive disease features including >5 CTCs and presence of CTC clusters were strongly associated with HER2+ CTCs (OR 15.72, 95% CI 6.89-35.8 and 8.97, 95% CI 3.23-24.89, respectively). Of 168 pts with ctDNA analysis, ERRB2 aberrations were seen in 22% of pts and were significantly associated with HER2+ CTCs (OR of 3.74, 95% CI 1.45-9.63). On multivariate analysis, the associations with >5 CTCs and ERBB2 alterations in ctDNA remained statistically significant. The associations of HER2+ CTCs with bone disease, >5 CTCs, CTC clusters, and ERBB2 alterations in ctDNA, and the inverse relationship with IBC were consistent when HER2+ CTCs were evaluated as a continuous variable with Kruskal-Wallis testing. Among pts without HER2+ CTCs at baseline, the time to detection of HER2+ CTCs correlated with the presence of bone metastases (HR 3.40, 95% CI 1.14-10.19), >5 CTCs (3.77, 95% CI 1.33-10.70), and visceral disease (HR 3.00, 95% CI 1.07-8.44).
Conclusions: HER2+ CTCs are common in ABC, independent of HER2 status of the tumor, and, in fact, common in the luminal BC. HER2+ CTCs were also strongly associated with CTC characteristics of aggressive disease with poor survival (CTCs clusters and >5 CTCs) and ERBB2 aberrations in ctDNA. Further studies will be investigating the role of HER2+ CTCs in endocrine resistance and the potential of anti-HER2 therapy in this unique CTC-defined setting.
Citation Format: Shah AN, Gerratana L, Davis AA, Zhang Q, Zhang Y, Rossi G, Wang C, Strickland K, Yang H, Flaum L, Abu-Khalaf M, Behdad A, Ye Z, Platanias L, Gradishar WJ, Cristofanilli M. HER2-positive circulating tumor cells (CTCs) in advanced breast cancer (BC): A feature independent of BC subtype [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-01-19.
Collapse
Affiliation(s)
- AN Shah
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - L Gerratana
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - AA Davis
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - Q Zhang
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - Y Zhang
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - G Rossi
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - C Wang
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - K Strickland
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - H Yang
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - L Flaum
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - M Abu-Khalaf
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - A Behdad
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - Z Ye
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - L Platanias
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - WJ Gradishar
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| | - M Cristofanilli
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA
| |
Collapse
|
8
|
Gerratana L, Zhang Q, Wang C, Shah A, Davis AA, Ye Z, Zhang Y, Abu-Khalaf M, Flaum L, Strickland K, Rossi G, Behdad A, Gradishar W, Platanias L, Yang H, Cristofanilli M. Abstract P5-17-02: Dissecting the biology of inflammatory breast cancer (BC) through cell free DNA and a circulating tumor cells (CTC)-derived signature. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-17-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The biological characteristics conferring Inflammatory BC's (IBC) distinctive and aggressive clinical features are currently not fully clarified. The aim of this study is to dissect IBC's biology through the integration of DNA and CTC-based circulating biomarkers.
Methods: This study retrospectively analyzed 251 Advanced BC (ABC) patients (pts) treated and longitudinally characterized for CTCs and circulating tumor DNA (ctDNA) at Thomas Jefferson University (Philadephia, PA) and Northwestern University (Chicago, IL). CTCs were enumerated through CellSearch (Menarini Silicon Biosystems), and characterized for HER2 expression using the CellSearch CXC Kit, while ctDNA was analyzed using the Guardant360 NGS assay (Guardant Health) and its percentage (%ctDNA) was classified based on the previously reported cut-off of 5.7% (Gerratana et al 2018). A subset of 117 pts was further characterized for circulating cell-free DNA (ccfDNA) through Qubit® dsDNA HS quantitation Assay (Thermo Fisher Scientific) and quantitative real-time PCR assay for ALU DNA repeats on chromosome 1.Associations between clinical characteristics, CTCs-derived biomarkers and IBC were explored through Fisher's exact test; survival was tested though Cox regression and log-rank test.
Results: Of the total 251 pts, 115 were diagnosed with IBC. Among the 117 patients characterized for ccfDNA, 70 had IBC. Median ccfDNA was 1.59 for IBC (IQR 1.02-3.19) and 2.37 for non-IBC (nIBC) (IQR 1.13-3.52), P=0.27. Consistent results were observed for %ctDNA levels (median value: 2 vs 1.6). The impact on OS of ccfDNA after log transformation was significant for the total population (HR 1.73 95%CI: 1.11-2.69) but not in IBC pts (HR 1.40 95%CI: 0.84-2.34). On the other hand, ctDNA high pts had a significantly worse OS (nIBC: HR 5.34 95%CI: 1.70-18.81 P=0.004; IBC: HR 4.05 95%CI: 1.91-8.58 P< 0.001). In the ctDNA high subgroup no differences in total number of CTCs were observed between IBC and nIBC, while significantly lower CTCs were observed in ctDNA low IBC pts (P=0.0097). The ctDNA low IBC subgroup had a higher incidence of HER2 positive BC (P=0.003) and a significantly lower incidence of CTCs clusters (P=0.006), HER2 positive CTCs (P=0.041). Notably, no associations were observed with stage at baseline, number of metastatic sites, liver, lung and visceral involvement. On the other hand, the ctDNA_high IBC subgroup was characterized by a lower incidence in liver, bone and visceral involvement (P=0.017, P=0.014 and P=0.03 respectively) and a marginally high incidence in soft tissue involvement (0.084). Moreover, IBC diagnosis conferred a significantly worse prognosis only in the ctDNA low subgroup (OS at 12 months nIBC: 100% vs IBC: 70%; P=0.049), while no differences were observed in the ctDNA_high subgroup (OS at 12 months nIBC: 29% vs IBC: 26%; P=0.767).
Conclusion: ctDNA is able to stratify BC according to aggressiveness independently from the sites and type of metastases, both in the IBC and nIBC subgroups. IBC has a distinctive CTCs/ctDNA-based signature, in particular ctDNAlow pts have a lower incidence of HER2 positive CTCs and CTC clusters. This signature is probably due to predominant lymphatic metastatic spread and aggressive phenotype.
Citation Format: Gerratana L, Zhang Q, Wang C, Shah A, Davis AA, Ye Z, Zhang Y, Abu-Khalaf M, Flaum L, Strickland K, Rossi G, Behdad A, Gradishar W, Platanias L, Yang H, Cristofanilli M. Dissecting the biology of inflammatory breast cancer (BC) through cell free DNA and a circulating tumor cells (CTC)-derived signature [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-17-02.
Collapse
Affiliation(s)
- L Gerratana
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - Q Zhang
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - C Wang
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - A Shah
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - AA Davis
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - Z Ye
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - Y Zhang
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - M Abu-Khalaf
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - L Flaum
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - K Strickland
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - G Rossi
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - A Behdad
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - W Gradishar
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - L Platanias
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - H Yang
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| | - M Cristofanilli
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; University of Udine, Udine, UD, Italy; Thomas Jefferson University, Philadelphia, PA; Ospedale dell'Angelo – Ospedale SS. Giovanni e Paolo, Venezia, VE, Italy
| |
Collapse
|
9
|
Davis AA, Zhang Y, Behdad A, Taxter T, Strickland K, Santa-Maria C, Flaum L, Cruz MR, Platanias LC, Gradishar WJ, Cristofanilli M. Abstract P2-02-21: The utility and correlation of circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) based on HER2 positivity. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-02-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
CTCs are well-established prognostic and predictive biomarkers for metastatic breast cancer (MBC) and other solid tumors. ctDNA is emerging as a quantitative blood-based biomarker for monitoring genomic alterations and disease progression. We evaluated the clinical utility and correlation of these liquid biopsy molecular tools in a cohort of MBC patients.
Methods:
CTC samples were obtained from an ongoing, prospective study of blood based prognostic biomarkers for breast cancer patients. At this time, 71 patients and 98 total samples have been collected. CTC enumeration was performed using the CellSearchTM platform (Menarini, IT). Within this cohort, MBC patients who had ctDNA testing were identified. ctDNA testing was performed using Guardant360TM (Guardant Health, CA), a digital next-generation sequencing technology. Two groups were analyzed: (1) HER2-negative patients with CTC ≥ 5 in 7.5 ml of blood (2) HER2-positive patients who had been treated with HER2 targeted therapy.
Results:
22 samples (N=16 patients) were found with CTC ≥ 5 (range 8-904) and concurrent ctDNA testing (median timeframe between collection 0 days, range 0-42 days). There was a significant association between number of CTCs and the total number of genomic alterations detected in ctDNA (paired two sample t-test, p=0.012). In addition, CTC enumeration was significantly correlated with somatic alteration burden of the dominant clone (paired two sample t-test, p=0.023). The most common alterations detected in the blood were TP53 (55% of patients, 18 total mutations), PIK3CA (41% of patients, 15 total mutations), and ESR1 (32% of patients, 14 total mutations). For patients with HER2 positivity receiving HER2-targeted therapies (N=16 samples from 11 patients), only 18.8% of samples had detectable CTCs (all less than 5) as compared to 75.0% of samples with detectable ctDNA alterations. In N=12 samples with detectable ctDNA mutations, mean number of genomic alterations was 4.4 with mean somatic mutation burden of 2.95%.
CTCs detectedctDNA detectedCTC ≥ 5Mean number of ctDNA alterations+Mean somatic alteration burden+HER2- (only cases with CTC ≥ 5)100% (22/22)100% (22/22)100%6.716.1%HER2+ (all cases)18.8% (3/16)75.0% (12/16)0%4.42.95%+excludes ctDNA samples without detected genomic alterations
Conclusions:
In HER2-negative MBC patients, CTC enumeration was significantly correlated with the number of ctDNA genomic alterations and somatic alteration burden, indicating the potential for ctDNA as a prognostic, quantitative biomarker of tumor burden. In patients with HER2 positivity, ctDNA may be a more sensitive liquid biopsy tool given the rarity of detecting CTCs detection in this population using the CellSearchTM system. In HER2-positive patients, consideration of size-dependent selection of CTCs using filtration of cells that have undergone epithelial-mesenchymal transition may improve detection in this subgroup.
Citation Format: Davis AA, Zhang Y, Behdad A, Taxter T, Strickland K, Santa-Maria C, Flaum L, Cruz MR, Platanias LC, Gradishar WJ, Cristofanilli M. The utility and correlation of circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) based on HER2 positivity [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-02-21.
Collapse
Affiliation(s)
- AA Davis
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - Y Zhang
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - A Behdad
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - T Taxter
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - K Strickland
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - C Santa-Maria
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - L Flaum
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - MR Cruz
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - LC Platanias
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - WJ Gradishar
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| | - M Cristofanilli
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Northwestern University Feinberg School of Medicine, Chicago, IL; Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
10
|
Strickland K. The primary care management of leiomyoma-induced abnormal uterine bleeding. J Am Acad Nurse Pract 1996; 8:541-5; quiz 546-8. [PMID: 9305056 DOI: 10.1111/j.1745-7599.1996.tb00619.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- K Strickland
- Family Nurse Practitioners Program, University of Arizona, Tucson, USA
| |
Collapse
|
11
|
Strickland D, Gambrell R, Butzin C, Strickland K. 92280895 The relationship between breast cancer survival and prior postmenopausal estrogen use. Maturitas 1993. [DOI: 10.1016/0378-5122(93)90076-t] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Strickland DM, Gambrell RD, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992; 80:400-4. [PMID: 1495695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The growth of breast cancer may be mediated by endogenous or exogenous sex steroid hormones, particularly estrogen. However, neither contraceptive nor noncontraceptive estrogen use has been associated definitively with an increased risk of developing breast cancer. In this study, we addressed a corollary question: If a postmenopausal woman develops carcinoma of the breast, is her survival affected by previous use of replacement estrogen? Two hundred fifty-six postmenopausal women with breast cancer entered our Tumor Registry between 1972-1981, inclusive. Of these, 174 took no replacement estrogen before the diagnosis (never-users), 21 had used estrogen previously (past users), and 61 were taking estrogen at the time of diagnosis (current users). Survival analysis revealed a median survival of less than 84 months after diagnosis for never- and past users and greater than 143 months for current users, but these differences were not significant when controlled for stage of disease at diagnosis. We conclude that prior postmenopausal estrogen replacement therapy does not compromise survival in women who subsequently develop carcinoma of the breast.
Collapse
Affiliation(s)
- D M Strickland
- Department of Obstetrics and Gynecology, Wilford Hall United States Air Force Medical Center, Lackland Air Force Base, Texas
| | | | | | | |
Collapse
|
13
|
Abstract
The American Medical Association's Committee on Medical Aspects of Automobile Safety recommends that pregnant women use seat belts. Currently, all military installations, 39 states, and the District of Columbia mandate varying degrees of seat belt usage. A survey was conducted to evaluate seat belt usage in the antepartum population at the Wilford Hall United States Air Force Medical Center. Eighty-eight percent of the respondents used automobile safety restraints 100% of the time when driving, and 90% of the respondents used automobile safety restraints 100% of the time when riding as a passenger. Twenty-three percent, however, were uniformed or misinformed about seat belt safety procedures and practices during pregnancy. Increased education regarding seat belt safety would be beneficial to this population.
Collapse
Affiliation(s)
- T L Hammond
- Department of Obstetrics and Gynecology, Wilford Hall United States Air Force Medical Center, Lackland Air Force Base, TX 78236-5300
| | | | | | | |
Collapse
|
14
|
Abstract
Four horses were stabled and fed a diet of hay ad libitum, and 2 kg oats per animal per day, for a month. The basic diet was then supplemented with molybdenum, at a rate of 20 mg/kg dry matter for 4.5 months. For one month of this period the diet was supplemented also with sulphur at a rate of 1.2 g/kg dry matter. Analyses of jugular blood samples, obtained at intervals varying between two and 20 days, showed no evidence of a decline in total plasma copper or of an increased proportion of trichloroacetic acid (TCA) insoluble copper in plasma over this period. In separate studies, two other horses were given 99molybdenum (molybdate, 20 to 28 mg Mo, 4 mCi per animal) per os, initially while being fed the basic diet and later while maintained on the molybdenum supplemented diet. 99Molybdenum appeared rapidly in plasma, but the radioactivity was then quickly cleared (half-life 7 to 10 h). The 99molybdenum present was identified as (99Mo)-molybdate. There was no evidence of the persistent, protein-bound (99Mo)thiomolybdates which appear in ruminants. These studies indicate that increased dietary molybdenum is unlikely to interfere with copper metabolism in horses.
Collapse
Affiliation(s)
- K Strickland
- Veterinary Research Laboratory, Abbotstown, Co Dublin, Ireland
| | | | | | | |
Collapse
|
15
|
Strickland DM, Hauth JC, Widish J, Strickland K, Perez R. Amylase and isoamylase activities in serum of pregnant women. Obstet Gynecol 1984; 63:389-91. [PMID: 6199704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The data previously reported for serum amylase activity in the blood of pregnant women are conflicting with respect to normal values and the relationship of activity to duration of pregnancy. By use of a DuPont Automatic Clinical Analyzer, amylase activity in serum from the blood of 413 asymptomatic healthy women who were six to 40 weeks pregnant was determined. Samples with amylase activity greater than 100 IU/L were tested for pancreatic and salivary isoenzymes. In every case except one, the isoenzyme levels were normal. In the blood of all women, except this one, the serum amylase activity was less than 150 IU/L and mean serum amylase activity did not correlate with gestational duration. Amylase activities at all gestational ages did not differ from the activity in serum obtained from the blood of women six weeks post partum. The authors conclude that 1) serum amylase levels may be as high as 150 IU/L in the blood of normal pregnant women; 2) serum amylase activities vary widely among pregnant women, but not in a manner related to the stage of gestation; and 3) pregnancy does not cause elevation of serum amylase isoenzyme activity.
Collapse
|
16
|
Mellios A, Strickland K. Systematic management of food service. Case study: new oven may facilitate decentralization. Hospitals 1972; 46:93-6. [PMID: 5041237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|